Intellectual property news affecting business and everyday life
Thursday, July 29, 2004
J&J loses Hatch-Waxman case to Eon on Sporanox
A district court ruled that a generic version of Johnson & Johnson nail fungus drug Sporanox proposed by Eon does not infringe a company patent, the Janssen Pharmaceutica unit of J&J reported on July 29, 2004.
The decision affects only US sales of the drug, which, in 2004Q2, comprised only $32 million of worldwide sales of $170 million.
I'm a patent lawyer located in central New Jersey. I have a J.D. from the University of Chicago and a Ph.D. from Stanford University, where I studied graphite intercalation compounds at the Center for Materials Research. I worked at Exxon Corporate Research in areas ranging from engine deposits through coal and petroleum to fullerenes. An article that I wrote in The Trademark Reporter, 1994, 84, 379-407 on color trademarks was cited by Supreme Court in Qualitex v. Jacobson, 514 US 159 (1995) and the methodology was adopted
in the Capri case in N.D. Ill. An article that I wrote on DNA profiling was cited by the Colorado Supreme Court (Shreck case) and a Florida appellate court (Brim case). I was interviewed by NHK-TV about the Jan-Hendrik Schon affair. I am developing ipABC, an entity that combines rigorous IP analytics with study of business models, to optimize utilization of intellectual property. I can be reached at C8AsF5 at yahoo.com.